Pro: Access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatment

Pro: Access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatment

Inhaled corticosteroids (ICS) are the core component of asthma treatment and the only maintenance therapy known to prevent asthma death. There is currently no evidence that biologics prevent asthma death in people with asthma, and as such, biologics cannot be recommended as an alternative to ICS the...

Full description

Bibliographic Details
Main Authors: Anna C. Murphy, Claire Boddy, Peter Bradding
Format: Article
Language:English
Published: European Respiratory Society 2021-06-01
Series:Breathe
Online Access:http://breathe.ersjournals.com/content/17/2/210024.full
id doaj-44accaaa7bd0410995d2aabf439d2444
record_format Article
spelling doaj-44accaaa7bd0410995d2aabf439d24442021-08-11T08:48:06ZengEuropean Respiratory SocietyBreathe1810-68382073-47352021-06-0117210.1183/20734735.0024-20210024-2021Pro: Access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatmentAnna C. Murphy0Claire Boddy1Peter Bradding2 Dept of Respiratory Medicine, University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester, UK Dept of Respiratory Medicine, University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester, UK Dept of Respiratory Medicine, University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester, UK Inhaled corticosteroids (ICS) are the core component of asthma treatment and the only maintenance therapy known to prevent asthma death. There is currently no evidence that biologics prevent asthma death in people with asthma, and as such, biologics cannot be recommended as an alternative to ICS therapy. Taking the time to assess adherence and provide interventions and education to support patients in asthma self-management has been shown to improve patient outcomes. It is therefore our responsibility as healthcare professionals to ensure that patients are supported, educated and motivated to adhere to ICS therapy before progressing to biologic therapies.http://breathe.ersjournals.com/content/17/2/210024.full
collection DOAJ
language English
format Article
sources DOAJ
author Anna C. Murphy
Claire Boddy
Peter Bradding
spellingShingle Anna C. Murphy
Claire Boddy
Peter Bradding
Pro: Access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatment
Breathe
author_facet Anna C. Murphy
Claire Boddy
Peter Bradding
author_sort Anna C. Murphy
title Pro: Access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatment
title_short Pro: Access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatment
title_full Pro: Access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatment
title_fullStr Pro: Access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatment
title_full_unstemmed Pro: Access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatment
title_sort pro: access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatment
publisher European Respiratory Society
series Breathe
issn 1810-6838
2073-4735
publishDate 2021-06-01
description Inhaled corticosteroids (ICS) are the core component of asthma treatment and the only maintenance therapy known to prevent asthma death. There is currently no evidence that biologics prevent asthma death in people with asthma, and as such, biologics cannot be recommended as an alternative to ICS therapy. Taking the time to assess adherence and provide interventions and education to support patients in asthma self-management has been shown to improve patient outcomes. It is therefore our responsibility as healthcare professionals to ensure that patients are supported, educated and motivated to adhere to ICS therapy before progressing to biologic therapies.
url http://breathe.ersjournals.com/content/17/2/210024.full
work_keys_str_mv AT annacmurphy proaccesstoadvancedtherapiesforsevereasthmashouldberestrictedtopatientswithsatisfactoryadherencetomaintenancetreatment
AT claireboddy proaccesstoadvancedtherapiesforsevereasthmashouldberestrictedtopatientswithsatisfactoryadherencetomaintenancetreatment
AT peterbradding proaccesstoadvancedtherapiesforsevereasthmashouldberestrictedtopatientswithsatisfactoryadherencetomaintenancetreatment
_version_ 1721211495796178944

Similar Items